Amy Dupage

Amy DuPage is a seasoned professional in the field of translational science and biomarker development, currently serving as Director at Arcus Biosciences since August 2022, previously holding the position of Associate Director, Translational Science. Prior experience includes roles as Principal Scientist, Translational Development at Aruvant, and Sr. Scientist positions at 4D Molecular Therapeutics and Aduro Biotech, where focus was on advancing immune-oncology pipelines. Extensive background includes implementing biomarker strategies at CytomX Therapeutics, early discovery target validation at Amgen, and evaluating monoclonal antibodies for ALS at Biogen Idec. Early career roles at Rigel and Berlex Biosciences involved drug development and quality control assessments. Amy DuPage earned a PhD in Biology from Brandeis University in 2009.